NEW BRUNSWICK, NJ, November 15, 2021 / PRNewswire / – Today, Johnson & Johnson Innovation, LLC, in collaboration with Janssen Scientific Affairs, LLC, appointed Camden Coalition of Healthcare Providers, the Department of Psychiatry and the Behavioral Sciences of the Keck School of Medicine, University of Southern California, Emory University and Lucia Health Guidelines recipients of Decoding disparities QuickFire Challenge at the Reuters Total Health Summit.
“For communities of color in United States, we understand that health disparities can take many forms, including higher rates of chronic disease, increased disease burden and significant barriers to accessing care, âsaid Anastasia G. Daifotis, MD, Scientific Director, Janssen North America Pharmaceuticals, Janssen Scientific Affairs, LLC. âFor this reason, we are proud to launch this QuickFire Challenge to inspire and help advance research that could pave the way for more equitable health care and better health outcomes. ”
Each winner of this QuickFire Challenge attempts to inspire and advance data-driven methodologies or technologies with the potential to better detect, understand or reduce health disparities. For example:
- Camden Coalition of Healthcare Providers aims to promote continuity of care for people with mental health needs who present to the emergency department by developing the ability to collect, analyze and report data on the social and systemic barriers they face .
- Department of Psychiatry and Behavioral Sciences, Keck School of Medicine, University of Southern California aims to develop an innovative approach to providing community mental health services through integrated counseling within a cultural center for black college students.
- A team of Emory University aims to create a social determinants of health (SDOH) understanding score using new, but widely available data that can be linked to patients’ electronic health records (EHRs). The score will be used to improve a provider’s ability to tailor clinical recommendations for optimal management of patients with cardiovascular disease.
- Lucia’s Health Guidelines has created a cloud-based AI clinical decision support tool that has the potential to detect and treat atrial fibrillation at the point of care.
The challenge invited applications from innovators working on applied research methodologies, tools or technologies in therapeutic areas of interest to the Johnson & Johnson Janssen Pharmaceuticals with special emphasis on: mental health, cardiovascular disease and inflammatory bowel disease (IBD). Specific considerations included the integration of population health data to identify gaps within communities of color and provide actionable information to inform interventions to remove barriers to equitable access to health care throughout the lifespan. of the patient’s journey.
To help advance their research, awardees will receive a combined total of $ 600,000 in grant funding, access to the global Johnson & Johnson Innovation â JLABS network and mentoring experts from the Johnson & Johnson family of companies1.
âWe received exceptional responses from entrepreneurs, academics and researchers for the Decoding Disparities QuickFire challenge. Applicants have shown ingenuity in submitting numerous data-driven approaches designed to tackle the root causes of health inequalities, âsaid Melinda Richter, Global Manager, Johnson & Johnson Innovation – JLABS2. âWe are delighted to be working closely with the four award winners to help them develop their ideas and deliver potential breakthrough solutions to traditionally underserved communities. “
An independent panel evaluated and selected the winners using criteria that included the uniqueness, feasibility and generalizability of the idea; rigor of the approach; ability to collect and analyze factors driving disparities that could potentially inform strategies and tactics that improve health outcomes in racial / ethnic groups and underserved populations; the potential measurable impact of integrating data, analytics and patient engagement to improve population health outcomes both immediately and over the long term; and alignment with areas of strategic intervention and expertise for the Janssen pharmaceutical companies of Johnson & Johnson.
Johnson & Johnson Innovation developed the QuickFire Challenge platform with the aim of helping to deliver potentially breakthrough science and health solutions by encouraging students, entrepreneurs, researchers and start-ups to tackle certain of the world’s most difficult health problems.
For more information on QuickFire challenges, please visit: https://jlabs.jnjinnovation.com/quickfire-challenges.
About Johnson & Johnson Innovation
Johnson & Johnson Innovation LLC works in the pharmacy, medical device and consumer health industries to accelerate early stage transformational solutions by catalyzing the best ideas, wherever they are in the world. We do this by leveraging our in-depth scientific capabilities combined with a wide range of tools, including custom transaction structures, business creation, incubation and start-up services, capital investments and other models. innovative businesses that aim to meet the diverse needs of entrepreneurs, scientists and emerging. companies. Our goal is to help innovations in life sciences and health technologies thrive through collaboration and partnership with the global ecosystem, so that together we can change the trajectory of human health. Meet our passionate team of science and technology experts and learn how to collaborate with us at www.jnjinnovation.com.
About Johnson & Johnson Janssen Pharmaceutical Companies
At Janssen, we are creating a future where illness is a thing of the past. We are the pharmaceutical companies of Johnson & Johnson, working tirelessly to make this future a reality for patients around the world by fighting disease with science, improving access with ingenuity, and healing despair with heart. We focus on the areas of medicine where we can make the biggest difference: cardiovascular and metabolism, immunology, infectious diseases and vaccines, neuroscience, oncology and pulmonary hypertension. Learn more about www.janssen.com. follow us on @JanssenGlobal.
Cautions Regarding Forward-Looking Statements
This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding the announcement of the award of the Decoding Disparities QuickFire Challenge. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If the underlying assumptions prove to be inaccurate or if known or unknown risks or uncertainties materialize, actual results could differ materially from the expectations and projections of Johnson & Johnson Innovation LLC, Janssen Scientific Affairs, LLC and / or Johnson & Johnson . Risks and uncertainties include, but are not limited to: the potential that the expected benefits and opportunities of collaboration may not materialize or take longer to materialize than expected; challenges inherent in new product development, including uncertainty of clinical success and obtaining regulatory approvals; competition, including technological advances, new products and patents obtained by competitors; the uncertainty of the commercial success of new products; the company’s ability to successfully execute strategic plans; impact of business combinations and divestitures; patent challenges; changes in the behavior and spending habits or financial difficulties of buyers of health care products and services; and global health care reforms and trends in health care cost containment. A list and additional descriptions of these risks, uncertainties and other factors are available in Johnson & Johnson’s annual report on Form 10-K for the year ended. January 3, 2021, including in the sections entitled âCaution Regarding Forward-Looking Statementsâ and âSection 1A. Risk Factors âand in the company’s latest Quarterly Report on Form 10-Q, and the company’s subsequent filings with the Securities and Exchange Commission. Copies of these documents are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Johnson & Johnson Innovation LLC, Janssen Scientific Affairs, LLC and / or Johnson & Johnson do not undertake to update any forward-looking statements as a result of new information or future events or developments.
1 Subject to the execution of the agreements and the necessary documentation
2 Melinda Richter is employed by Johnson & Johnson Innovation LLC
SOURCE Johnson & Johnson Innovation